Lantern Pharma Q2 EPS $(0.44) Misses $(0.43) Estimate
Portfolio Pulse from bharat@benzinga.com
Lantern Pharma reported Q2 losses of $0.44 per share, missing the analyst consensus estimate of $0.43 by 2.33%. This represents a 7.32% increase in losses compared to the same period last year.

August 09, 2023 | 8:18 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Lantern Pharma's Q2 earnings missed analyst estimates, with losses increasing by 7.32% compared to the same period last year.
Lantern Pharma's Q2 earnings missed analyst estimates, which is typically a negative signal for the market. The increase in losses compared to the same period last year further exacerbates this negative impact. This could lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100